Skip to main content

Table 1 Baseline demographics and clinical characteristics of patients by race

From: Healthcare disparities in cardio oncology: patients receive same level of surveillance regardless of race at a safety net hospital

  Black
(N = 68)
White
(N = 41)
Hispanic (N = 33) Other
(N = 7)
P-value
Age at diagnosis (median, [IQR]) 58 (51, 66) 58 (52, 65) 53 (44, 59) 61 (43, 66) p = 0.54
Gender      p = 0.30
 Male 6 (8.8%) 9 (22.0%) 5 (15.2%) 1 (14.3%)  
 Female 62 (91.2%) 32 (78.0%) 27 (81.8%) 6 (85.7%)  
Insurance      p = 0.77
 Private insurance 37 (54.4%) 23 (56.1%) 16 (48.5%) 3 (42.9%)  
 Medicare 25 (36.8%) 12 (29.2%) 10 (30.3%) 3 (42.9%)  
 Medicaid 2 (2.9%) 1 (2.4%) 2 (6.1%) 0 (0.0%)  
 No insurance 4 (5.9%) 5 (12.2%) 5 (15.2%) 1 (14.3%)  
Income by ZIP codea      p < 0.00001
 Quartile 1 25 (36.8%) 2 (4.9%) 10 (30.3%) 3 (42.9%)  
 Quartile 2 13 (19.1%) 5 (12.2%) 14 (42.4%) 2 (28.6%)  
 Quartile 3 20 (29.4%) 11 (26.8%) 6 (18.2%) 0 (0.0%)  
 Quartile 4 10 (14.7%) 23 (56.1%) 3 (9.1) 2 (28.6%)  
Comorbidities
 HTN 46 22 15 3 p = 0.13
 HLD 18 16 11 2 p = 0.72
 CAD 4 6 2 0 p = 0.38
 Arrythmia 5 2 2 0 p = 0.82
 DM 19 10 9 1 p = 0.87
 Smoking 33 18 10 1 p = 0.18
 FH 20 12 7 2 p = 0.86
 Age > 65 16 11 5 1 p = 0.60
Procedures
 Coronary stents 1 1 0 0 p = 0.81
 Cardiac surgery 0 3 1 0 p = 0.13
Medications pre-chemo
Beta blocker 11 9 4 1 p = 0.72
ACEI/ARB 25 13 7 0 p = 0.13
Diuretic 7 1 2 0 p = 0.41
Hydralazine 2 0 0 0 p = 0.49
Nitrate 0 0 2 0 p = 0.37
MRA 0 0 0 0 p = 1
CCB 12 3 2 0 p = 0.26
Antiarrhythmic 0 0 0 0 p = 1
Aspirin 13 8 2 1 p = 0.35
Statin 13 10 5 0 p = 0.76
Cancer type      p = 0.036
 Breast cancer 57 (83.8%) 24 (58.5%) 24 (72.7%) 5 (71.4%)  
 Other cancerb 11 (16.2%) 17 (41.5%) 9 (27.3%) 2 (28.6%)  
Cancer stage      p = 0.98
 Stage 1 6 (8.8%) 3 (7.3%) 2 (6.1%) 1 (14.3%)  
 Stage 2 32 (47.1%) 18 (43.9%) 18 (54.5%) 3 (42.9%)  
 Stage 3 14 (20.6%) 9 (22.0%) 5 (15.2%) 1 (14.3%)  
 Stage 4 16 (23.5%) 12 (29.3%) 7 (21.2%) 2 (28.6%)  
Chemotherapy      p = 0.50
 Doxorubicin 24 (35.3%) 22 (53.7%) 15 (45.5%) 3 (42.9%)  
 Herceptin 39 (57.4%) 15 (36.6%) 14 (42.4%) 4 (57.1%)  
 Doxorubicin and herceptin 5 (7.4%) 4 (9.8%) 4 (12.1%) 0 (0.0%)  
Ejection fraction      p = 0.75
 Decreasec 19 (27.9%) 11 (26.8%) 6 (18.2%) 2 (28.6%)  
 No decrease 49 (72.1%) 30 (73.2%) 27 (81.2%) 5 (71.4%)  
Current status      p = 0.60
 In remission 21 (30.1%) 14 (34.1%) 11 (33.3%) 3 (42.9%)  
 Not in remission 39 (57.4%) 19 (46.3%) 20 (60.6%) 3 (42.9%)  
 Deceased 8 (11.8%) 7 (17.1%) 1 (3.03%) 1 (14.3%)  
  1. aZIP codes were used to group patients into quartiles based on median annual household income, with quartile 1 earnings $0 - $18,900, quartile 2 earnings $19,000 – 32,800, quartile 3 earnings 32,900 – 56,000, quartile 4 earnings $57,000 – 130,300
  2. bOther cancer types included lymphoma (Hodgkin’s, T-cell, large cell), multiple myeloma, esophageal cancer, gastric cancer, abdominal desmoid cancer, carcinoid tumor, bladder cancer, ovarian cancer, endometrial cancer, leiomyosarcoma, metastatic cancer with an unknown primary
  3. cDecrease in EF defined by symptomatic reduction in EF by at least 5% to less than 55% or an asymptomatic reduction in EF by at least 10% to less than 55% according to Cardiac Review and Evaluation Committee of Trastuzumab-associated Cardiotoxicity
\